权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort)

针对 HPV 相关非艾滋病定义癌症的新型靶向疗法（生物样本/生物队列）

基本信息

批准号：
10620083
负责人：
STEVEN Terry ROSEN
金额：
$ 25万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2022-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10620083
关键词：
AIDS related cancer Blood COVID-19 vaccine Cell Death Cell Line Data Dependence Development Engineering Etiology Gene Delivery Gene-Modified Genome Genomics Goals Grant Growth HIV HPV-High Risk Head Cancer Head and Neck Cancer Head and neck structure Human Papilloma Virus-Related Malignant Neoplasm Human Papillomavirus Human papillomavirus 16 Individual Infection Intervention Maintenance Malignant Neoplasms Malignant neoplasm of anus Malignant neoplasm of cervix uteri Methods Mission Modeling Neck Oncogenes Oncogenic Viruses Oncornaviruses Patient Representative Persons Promoter Regions Proteins Public Health RNA delivery Repressor Proteins Research System Testing Therapeutic Therapeutic Intervention United States National Institutes of Health Viral Viral Genes Viral Oncogene Vulnerable Populations Work Zinc Fingers anti-cancer carcinogenicity co-infection combat high risk human papilloma virus oncogene in vivo in vivo Model innovation leukemia lipid nanoparticle mouse model nanoparticle delivery new therapeutic target novel novel therapeutic intervention oncogene addiction patient derived xenograft model success targeted treatment therapeutic RNA therapeutic development therapeutic gene therapeutic target tumor

项目摘要

Project Summary/Abstract Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort) The incidents of non-AIDS-defining cancers (NADC) are increasing in HIV-infected individuals (HIVIIs), urging the development of therapeutic interventions. Many HIV-associated cancers are a result of co-infections with oncogenic viruses, and the high-risk human papillomavirus (HPV) is prevalent in the development of several NADCs, including head-and-neck (HNC) and anal cancers. Importantly, the HPV viral oncogenes are involved in the transformation and maintenance of these cancers and are considered unique targets in HPV-associated malignancies. Often considered `undruggable', these viral genes are susceptible to targeted gene therapeutic strategies and we have developed a novel, potent zinc finger protein (ZFP) that can strongly repress viral oncogenes to elicit anti-cancer effects; a promising approach to HPV-associated NADCs. Furthermore, lipid nanoparticles (LNPs) are a therapeutically relevant non-viral delivery system, which we have used previously for in vivo delivery of RNA-based therapeutics. Importantly, even though the HPV oncogenes represent viable therapeutic targets, there are no studies investigating the potential anti-proliferative effect of targeting the viral oncogenes in HPV-associated tumors from HIVIIs in vivo. Our long-term goal is to develop innovative interventions for the treatment of virally driven cancers emerging in HIVIIs, with the objective of this project to use LNP-delivered ZFP repressors to inactive HPV oncogenes in NADCs. Guided by our strong preliminary data and expertise using targeted repressors and nanoparticle delivery systems, we propose two complementary but distinct objectives, 1) the characterization of novel, potent ZFP repressors for anti-proliferative effects in HPV- associated cell line models relevant to NADCs, and 2) to assess LNP-delivered anti-HPV effectors to inhibit HPV-associated HNCs from HIVIIs in a patient-derived xenograft (PDX) murine model. Collectively, this work will be impactful by developing an innovative targeted repressor to inhibit HPV-associated NADCs, offering a novel intervention to malignancies increasing in HIVIIs.

项目总结/摘要 HPV相关非AIDS定义癌症的新型靶向治疗（生物样本/生物队列）非艾滋病定义的癌症（NADC）在艾滋病毒感染者（HIVII）中的发病率正在增加，治疗干预的发展。许多与艾滋病毒相关的癌症是与以下疾病合并感染的结果：人乳头瘤病毒（HPV）是一种常见的致癌病毒，高危型人乳头瘤病毒（HPV）在几种肿瘤的发展中普遍存在。 NADC，包括头颈部（HNC）和肛门癌。重要的是，HPV病毒癌基因参与在这些癌症的转化和维持中，被认为是HPV相关性肿瘤的独特靶点。恶性肿瘤。这些病毒基因通常被认为是“坚不可摧的”，对靶向基因治疗很敏感我们已经开发出一种新的，有效的锌指蛋白（ZFP），可以强烈抑制病毒致癌基因引发抗癌作用; HPV相关NADC的有前途的方法。此外，脂质纳米颗粒（LNP）是一种治疗相关的非病毒递送系统，我们以前曾用于基于RNA的治疗剂的体内递送。重要的是，即使HPV癌基因代表了可行的治疗靶点，没有研究调查靶向病毒的潜在抗增殖作用。体内来自HIVIIs的HPV相关肿瘤中的癌基因。我们的长期目标是发展创新治疗艾滋病毒感染者中出现的病毒驱动的癌症的干预措施，该项目的目标是使用LNP递送的ZFP阻遏物使NADC中的HPV癌基因失活。根据我们的初步数据，和专业知识，使用靶向阻遏物和纳米颗粒输送系统，我们提出了两个互补的，但不同的目的，1）表征新的，有效的ZFP阻遏物在HPV中的抗增殖作用，与NADC相关的相关细胞系模型，和2）评估LNP递送的抗HPV效应物以抑制在患者来源的异种移植（PDX）鼠模型中来自HIVII的HPV相关HNC。总的来说，这项工作将通过开发一种创新的靶向阻遏物来抑制HPV相关的NADC，对HIV感染者恶性肿瘤增加的新干预措施。